 |
市場調查報告書
糖尿病性胃輕癱治療的全球市場 - 市場規模，佔有率，預測，機會分析Diabetic Gastroparesis Treatment Market: By Product Type, By Disease Indication, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027 |
||||||
| 出版商 | Coherent Market Insights | 商品編碼 | 931849 | ||||
| 出版日期 | 內容資訊 | 英文 171 Pages 商品交期: 2-3個工作天內 |
|||||
| 價格 |
|
||||||
| 糖尿病性胃輕癱治療的全球市場 - 市場規模，佔有率，預測，機會分析 Diabetic Gastroparesis Treatment Market: By Product Type, By Disease Indication, By Distribution Channel, and By Region - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027 | ||
| 出版日期: 2020年03月05日 | 內容資訊: 英文 171 Pages |
|
糖尿病性胃輕癱，伴隨糖尿病相關的消化器官系統的問題。慢性糖尿病，阻礙各種內臟器官和含有迷走神經的神經系統的功能。迷走神經，控制排空胃的活動或排空胃的時間長度，即快或慢。損傷的迷走神經給予消化的影響，是食物在體內的殘留量超出需要。這個狀態被稱作胃輕癱，好發於第一型糖尿病，不過，第二型糖尿病的患者也會發病。根據鼻腔用噴霧等新治療選擇的調查開發，在預測期間內預計促進市場成長。另一方面，由於處方藥的改善相關臨床性證據的缺乏，臨床試驗的中止/結束等要素，預計妨礙市場成長。
本報告提供全球糖尿病性胃輕癱市場相關調查分析，市場概要，市場規模與預測，各市場區隔的市場分析，各地區的市場分析，競爭情形等相關的系統性資訊。
Diabetic gastroparesis involves digestive system issue associated with diabetes. Chronic Diabetes hampers functioning of various organs, and nervous system including vagus nerve. Vagus nerve controls stomach emptying activity or the time duration for stomach emptying i.e. how quick or slow. Damaged vagus serve affects digestion, and food stays for longer time in the body than required. This condition is called as gastroparesis, and is more common in people with type 1 diabetes, though type 2 diabetes patients can also get it. Research and development of newer treatment options such as nasal sprays is expected to support growth of the market over the forecast period. For instance, on 27 January 2020, Evoke Pharma, Inc., received Notice of Allowance for the Gimoti trademark from United States Patent and Trademark Office (USPTO). Gimoti is a nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. It is currently under review process for New Drug Disease Indication (NDA) by U.S. FDA and has a target Prescription Drug User Fee Act (PDUFA) of June 19, 2020.
Restraints of the Global Diabetic Gastroparesis Treatment Market
Factors such as lack of clinical evidence on improvement offered by prescription drugs, withdrawal/termination of clinical trials is also expected to hamper growth of the market.
This report provides in-depth analysis of the global diabetic gastroparesis treatment market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019-2027), considering 2018, as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
It profiles leading players in the global diabetic gastroparesis treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include Janssen Global Services, LLC, Cardinal Health, Inc., Evoke Pharma, Inc., Salix Pharmaceuticals, Inc., Alfa Wassermann SPA, Abbott Laboratories, Medtronic Plc., C. R. Bard, Inc. (Becton, Dickinson and Company), Rhythm Pharmaceuticals, Inc., Boston Scientific Corporation, Kimberly-Clark Corporation, Vanda Pharmaceuticals, Inc., and Allergan, plc.
Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
The global diabetic gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.
Detailed Segmentation
Global Diabetic Gastroparesis Treatment Market, By Product Type:
Drugs
Gastroprokinetic Agents
Antiemetic Agents
Botulinum Toxin
Surgical Treatment Products
Gastric Electrical Stimulation (GES) Device
Percutaneous Endoscopic Gastrostomy (PEG) Kit
Parenteral Nutrition
Global Diabetic Gastroparesis Treatment Market, By Disease Indication:
Compensated Gastroparesis
Gastric Failure
Global Diabetic Gastroparesis Treatment Market, By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Diabetic Gastroparesis Treatment Market, By Geography:
North America
By Product Type
Drugs
Gastroprokinetic Agents
Antiemetic Agents
Botulinum Toxin
Surgical Treatment Products
Gastric Electrical Stimulation (GES) Device
Percutaneous Endoscopic Gastrostomy (PEG) Kit
Parenteral Nutrition
By Disease Indication
Compensated Gastroparesis
Gastric Failure
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.S.
Canada
Europe
By Product Type
Drugs
Gastroprokinetic Agents
Antiemetic Agents
Botulinum Toxin
Surgical Treatment Products
Gastric Electrical Stimulation (GES) Device
Percutaneous Endoscopic Gastrostomy (PEG) Kit
Parenteral Nutrition
By Disease Indication
Compensated Gastroparesis
Gastric Failure
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
By Product Type
Drugs
Gastroprokinetic Agents
Antiemetic Agents
Botulinum Toxin
Surgical Treatment Products
Gastric Electrical Stimulation (GES) Device
Percutaneous Endoscopic Gastrostomy (PEG) Kit
Parenteral Nutrition
By Disease Indication
Compensated Gastroparesis
Gastric Failure
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
By Product Type
Drugs
Gastroprokinetic Agents
Antiemetic Agents
Botulinum Toxin
Surgical Treatment Products
Gastric Electrical Stimulation (GES) Device
Percutaneous Endoscopic Gastrostomy (PEG) Kit
Parenteral Nutrition
By Disease Indication
Compensated Gastroparesis
Gastric Failure
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Middle East:
By Product Type
Drugs
Gastroprokinetic Agents
Antiemetic Agents
Botulinum Toxin
Surgical Treatment Products
Gastric Electrical Stimulation (GES) Device
Percutaneous Endoscopic Gastrostomy (PEG) Kit
Parenteral Nutrition
By Disease Indication
Compensated Gastroparesis
Gastric Failure
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country:
GCC
Israel
Rest of Middle East
Africa
By Product Type
Drugs
Gastroprokinetic Agents
Antiemetic Agents
Botulinum Toxin
Surgical Treatment Products
Gastric Electrical Stimulation (GES) Device
Percutaneous Endoscopic Gastrostomy (PEG) Kit
Parenteral Nutrition
By Disease Indication
Compensated Gastroparesis
Gastric Failure
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Country/Region:
Central Africa
South Africa
North Africa
Company Profiles
Janssen Global Services, LLC *
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Cardinal Health, Inc.
Evoke Pharma, Inc.
Salix Pharmaceuticals, Inc.
Alfa Wassermann SPA
Abbott Laboratories
Medtronic Plc.
C. R. Bard, Inc. (Becton, Dickinson and Company)
Rhythm Pharmaceuticals, Inc.
Boston Scientific Corporation
Kimberly-Clark Corporation
Vanda Pharmaceuticals, Inc.
Allergan, plc.
"*" marked represents similar segmentation in other categories in the respective section.
